Regarding rapamycin‐related immune effects, a randomized placebo‐controlled phase 2a clinical trial did show that a low dose combination of a catalytic (BEZ235) plus an allosteric (RAD0001) mTOR inhibitor that selectively inhibits TORC1 had a significant decrease in the rate of reported infections after 1 year (Mannick et al. 2018). The gene discussed is CRTC1; the disease is infection.